Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/28/2026

1. NVDA
2. MPLT
3. USO
4. BSP
5. SPY
6. XFLT
7. HCA
8. ITG
9. CNI
10. CAPR

Go back to Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
(NASDAQ: APVO) Delayed: 4.21 -0.18 (4.1%)
Previous Close $4.39    52 Week High $4.33 
Open $4.38    52 Week Low $1.80 
Day High $4.45    P/E N/A 
Day Low $4.17    EPS $0.00 
Volume 38,012